Personalized treatment for advanced breast cancer
Part of Cancer clinical trials.
This trial uses information from a biopsy of your tumor to help choose the best treatment for advanced or metastatic hormone receptor-positive breast cancer. The goal is to find a therapy that works better for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative.
- Your cancer has grown during or after hormone therapy, or within 2 years of finishing a CDK4/6 inhibitor treatment.
- You are able to have a biopsy (tissue sample) taken from your tumor.
- You have not had certain prior treatments for metastatic breast cancer, such as capecitabine, PI3K inhibitors, mTOR inhibitors, SERDs, or HER2-targeted therapy.
- You do not have untreated or active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
Hear when a new Anatomic Stage III Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.